SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

When people with systemic lupus erythematosus (SLE) actively participate in shared decision-making (SDM) about their disease with their doctors’, trust is likely to increase. A new study found that ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol Hill purple at the 2026 National Lupus Advocacy Summit this April!

The new EULAR recommendations were developed by a multidisciplinary task force of patient research partners, nurses, and health care professionals from rheumatology as well as experts in physiotherapy ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that ...

SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

Over the past two decades, management of pain in patients with systemic lupus erythematosus (SLE) has come to rely less on higher-risk therapies like opioids, although prescribing intensity remains ...

Like in other chronic inflammatory disorders, achieving disease activity control in SLE requires the application of the treat-to-target strategy. This approach requires setting clear treatment targets ...

The SLECRISK tool for predicting cardiovascular disease among patients with systemic lupus erythematosus produces more accurate predictions compared with the American College of Cardiology/American ...